

AUTHOR INDEX

May 1, 1988

- Aarskog, D., 2458
Aitokallio-Tallberg, A. M., 2396
Aksnes, L., 2458
Alvarez, E., 2440
Amlot, P., 2610
Aoki, N., 2348
Ariyoshi, Y., 2544
Augeron, C., 2498
- Bakke, A., 2458
Bassin, R. H., 2483
Bechhofer, R., 2561
Bender, M. A., 2579
Bickers, D. R., 2361
Bik, D. P., 2361
Blum, R. H., 2574
Bonadonna, G., 2314
Borden, E. C., 2329
Boschelli, D., 2421
Boyd, D. D., 2469
Brahmi, Z., 2399
Brattain, D. E., 2469
Brattain, M. G., 2469
Bregman, C. L., 2538
Brown, A., 2610
Broxmeyer, H. E., 2399
Bryan, G. T., 2329
Buchsbaum, D. J., 2475
Burns, H. J. G., 2590
Bursch, W., 2462
- Calman, K. C., 2590
Carlson, D. A., 2353
Chan, V., 2335
Ciardiello, F., 2483
Cleary, K. R., 2353
Collins, L. S., 2335, 2342
Comis, R. L., 2568
Conlon, J. M., 2412
Cook, J. A., 2417
- Daniels, A., 2446
Daniels, J. R., 2446
Das, M., 2361
Davies, J., 2590
Defendi, V., 2505
Dennis, R. D., 2524
Diwan, B. A., 2492
Doppler, W., 2454
Dreyfuss, Y., 2451
Dunleavy, S., 2574
- Elliott, B. E., 2440
Ellis, A., 2404
- Faraggiana, T., 2451
Fearon, K. C. H., 2590
Fiebig, H-H., 2550
Fiore, J., 2579
Fodor, P. A., 2475
Folkl, R., 2585
Foon, K. A., 2475
Ford, S. M., 2475
Fossati, G., 2372
Fox, M. H., 2417
Freyer, J. P., 2432
Fukao, K-i., 2555
Fulton, R. J., 2618, 2626
- Galivan, J., 2421, 2426
- Gambacorti-Passerini, C., 2372
Gatenby, R. A., 2568
Gewirtz, D., 2404
Ghetie, M-A., 2610
Ghetie, V., 2610
Giavazzi, R., 2353
Glowinski, I. B., 2382
Golas, C. L., 2388
Green, M. D., 2574
Grimelius, L., 2412
Gross, L., 2451
Grunicke, H. H., 2454
Gutterman, J. U., 2604
- Hank, J. A., 2561
Hanna, D. E., 2475
Hansell, D. T., 2590
Harper, P. A., 2388
Hatcher, J. F., 2329
Herberman, R. B., 2596
Herman, T. S., 2335, 2342
Hickey, T. D., 2585
Hino, T., 2531
Hochster, H. S., 2574
Hofmann, J., 2454
Horii, Y., 2531
Hornback, N. B., 2399
Hosoi, H., 2531
Houghton, A. N., 2440
Hu, H., 2492
Huber, B. E., 2382
- Inaba, K., 2366
Irimura, T., 2353
- Janossy, G., 2610
Johnson, J. P., 2524
Johnson, T. B., 2426
Juni, J. E., 2475
- Kato, Taiji, 2531
Kato, Takuma, 2366
Kaufmann, M. E., 2335
Kayata, Y., 2555
Kazakoff, P., 2377
Kemshead, J. T., 2531
Kerbel, R. S., 2440
Kerwar, S. S., 2421
Khan, W. A., 2361
Kidwell, W. R., 2483
Kim, N., 2483
Kitaura, M., 2366
Klaunig, J. E., 2519
Kleinerman, E. S., 2604
Knowles, P. P., 2610
Knowles, R. D., 2604
Kohler, P. C., 2561
Kripke, M. L., 2325
- Laboisie, C. L., 2498
Lachman, L. B., 2604
Leonard, R. C., 2579
Levine, A. E., 2469
Liebes, L. F., 2574
Litwin, S., 2568
Loh, C., 2335
Lu, L., 2399
Lubet, R. A., 2492
- Macera, M. J., 2585
- Magee, P. N., 2313
Maly, K., 2454
Maoret, J-J., 2498
Masters, B. A., 2538
May, R. D., 2610
McGrath, H. A., 2585
McGregor, G. P., 2412
McKnight, M. K., 2469
McNutt, N. S., 2585
Miller, M. J., 2382
Moldofsky, P. J., 2568
Moore, K. H., 2561
Morgan, D., 2505
Morioka, H., 2531
Muggia, F. M., 2574
Mukhtar, H., 2361
Munger, C., 2404
Muramatsu, S., 2366
Murohashi, I., 2348
- Nair, M. G., 2426
Nakahira, K., 2366
Nara, N., 2348
Nimec, Z., 2421
Nims, R. W., 2492
- Obata, Y., 2544
O'Brien, J., 2568
Ochs, H., 2462
O'Dwyer, J., 2568
Ohyama, Y., 2555
Okey, A. B., 2388
Okuda, K., 2555
Oproiu, A., 2596
Oronsky, A. L., 2421
Ortlieb, B., 2550
Ota, D. M., 2353
Ota, K., 2544
- Parmiani, G., 2372
Parzefall, W., 2462
Pecoraro, G., 2505
Pislarasu, M., 2596
Plumb, J. A., 2590
Posnett, D. N., 2585
Preston, T., 2590
Price, J., 2353
- Radrizzani, M., 2372
Randolph, J., 2404
Relf, M., 2610
Rhee, M., 2421
Rice, J. M., 2492
Riethmüller, G., 2524
Rivoltini, L., 2372
Rizzino, A., 2377
Rodolfo, M., 2372
Romerdahl, C. A., 2325
Rosenberg, I., 2505
Rosenthal, N. S., 2561
Rubin, H., 2512
Ruch, R. J., 2519
Rudert, F., 2550
Ruff, E., 2377
- Salomon, D. S., 2483
Sanfilippo, B., 2483
Sato, T., 2544
Sawada, T., 2531
Schempp, W., 2550
Schriever, F., 2524
- Schulte-Hermann, R., 2462
Scott, R. A., 2585
Shapiro, D., 2590
Shen, R-N., 2399
Shenkin, A., 2590
Shimizu, S., 2366
Shively, J. E., 2550
Sidky, Y. A., 2329
Sinkule, J. A., 2475
Sondel, P. M., 2561
Sosman, J. A., 2561
Speyer, J. L., 2574
Spiegel, R. J., 2574
Sternlicht, M., 2446
Stites, M. S., 2475
Storer, B., 2561
Sugimoto, T., 2531
Sulica, A., 2596
Supino, R., 2372
Suzuki, T., 2348
Szabo, P., 2585
- Takada, K., 2555
Takahashi, T., 2544
Tanimoto, Y., 2555
Taranu, D., 2596
Tay, L. K., 2538
Teicher, B. A., 2335, 2342
Thim, L., 2412
Thompson, J. A., 2550
Thompson, M. H., 2579
Thorpe, P. E., 2610
Till, M., 2610
Tortora, G., 2483
Triadou, N., 2498
Trydal, T., 2458
Tucker, T. F., 2618
- Ueda, R., 2544
Uhr, J. W., 2610, 2618, 2626
Uno, K., 2366
Utsumi, K. R., 2544
- Valagussa, P., 2314
Viinikka, L. U., 2396
Viola, M. V., 2579
Vitetta, E. S., 2610, 2618, 2626
von Kleist, S., 2550
- Wallace, P. M., 2610
Wallin, G., 2412
Wang, Z. Y., 2361
Warber-Match, S. L., 2475
Ward, J. M., 2492
Watanabe, H., 2544
Weber, B., 2550
Weiner, L. M., 2568
Wernz, J. C., 2574
Widman, T., 2574
Williams, P. D., 2538
Wirth, P. J., 2382
Woods, K., 2404
- Yamaguchi, Y., 2366
Yamashita, Y., 2348
Yamori, T., 2353
Yanagihara, K., 2483
Yanovich, S., 2404
Ylikorkala, R. O., 2396
Yoshiga, K., 2555
Young, P., 2399
- Zimmermann, W., 2550



AMERICAN ASSOCIATION FOR CANCER RESEARCH

INFORMATION ON APPLICATION FOR ACTIVE AND CORRESPONDING MEMBERSHIP

BENEFITS OF MEMBERSHIP

The American Association for Cancer Research (AACR) is a scientific society consisting of laboratory and clinical cancer researchers. It was founded in 1907 "to bring together active investigators of the cancer problem for presentation and discussion of new or significant observations; and to foster research in cancer and other phenomena of growth." Members of the AACR enjoy the following benefits:

1. a subscription to the journal *Cancer Research* at the reduced member rate;
2. the privilege of sponsoring an abstract for presentation at the AACR annual meeting;
3. an advance copy of the Program and *Proceedings* pertaining to each annual meeting;
4. a reduced registration rate at the annual meeting;
5. early notification of events in the AACR's new series of small scientific meetings;
6. subscriptions to any future AACR journals at reduced member rates;
7. preferred access to the AACR Employment Register;
8. the receipt of AACR newsletters, meeting announcements, and an up-to-date membership directory.

QUALIFICATIONS FOR MEMBERSHIP

Active membership in the AACR is open to investigators who live in the Americas, and who have conducted two years of meritorious research that has resulted in publications relevant to cancer. If a candidate is working in a research area not directly related to the cancer field but has conducted research of exceptional scientific merit, he or she may also qualify for membership.

Corresponding membership is open to qualified persons who are not residents of the Americas. The requirements for corresponding membership are the same as those for active membership. Visiting scientists from outside the Americas who intend to return to their countries of origin soon after submitting their applications should apply for corresponding membership. All other individuals should apply for active membership and transfer to corresponding status at a later date if they should leave the Americas.

PROCEDURES FOR APPLICATION

There are two deadlines for receipt of a membership application: August 1 and December 1 of each year. The Membership Committee will review all complete applications for active membership that have been received by these deadlines and will submit recommendations on each candidate to the Board of Directors, which formally elects all members. The same procedure is followed by the Special Memberships Committee, which receives applications for corresponding membership. Applicants who meet the August 1 deadline will be notified of the Board's decision in November, and, if elected, will be eligible to sponsor an abstract for the annual meeting of the AACR to be held the following Spring. Applicants meeting the December 1 deadline will be notified about their election in March.

A complete application consists of the following material:

1. 6 copies of the form on the opposite side of this page, with all requested information provided.

2. 5 copies of the candidate's most current curriculum vitae and bibliography.
3. 5 copies of a letter of recommendation from a nominator who is an active, emeritus, or honorary member of the AACR (at least one copy must be a signed, original letter). This letter should describe the candidate's achievements in laboratory research, clinical investigations, or epidemiological research, and it should affirm that this research adheres to accepted ethical standards.—OR—The nominator may supply the responses requested at the bottom of the application form in the section entitled "STATEMENT OF SUPPORT" (at least one copy of the form must be the signed original).
4. 5 copies of a letter of recommendation as described in Item 3. above from a seconder who is an active, emeritus, or honorary member of the AACR (at least one copy must be a signed, original letter).—OR—The seconder may supply the responses requested at the bottom of the application form in the section entitled "STATEMENT OF SUPPORT" (at least one copy of the form must be the signed original).
5. 5 reprints of each of two publications on which the candidate appears as author.

All material should be collated into five complete sets with the original application form as a covering document and sent to the address given below. Questions regarding procedures for membership application may also be directed to the following address:

American Association for Cancer Research
Temple University School of Medicine
West Building, Room 301
Broad and Tioga Streets
Philadelphia, PA 19140
215/221-4565

RESPONSIBILITIES OF MEMBERSHIP

Candidates should be aware of the following responsibilities of membership in the AACR. Active members must pay annual dues, a major portion of which is designated for a subscription to the AACR's official publication outlet, *Cancer Research*. Newly elected members of the AACR who have already purchased subscriptions to *Cancer Research* at the higher, nonmember rate will receive reimbursement of the unused portion of that subscription once their first year's membership dues are paid in full.

All corresponding members elected after May 23, 1985, are required to pay an annual assessment in lieu of dues. This assessment, which is equivalent to that portion of the regular dues that pertains to support of activities other than the journal *Cancer Research*, is imposed to defray the cost of sending AACR publications to members outside the Americas. Corresponding members may, if they wish, subscribe to *Cancer Research* at the reduced member rate.

Successful candidates will be expected to begin paying dues to the AACR in the year following receipt of their applications; e.g., successful applicants who meet either the August 1, or December 1, 1988 deadlines will begin to pay dues in 1989.

Margaret Foti
Executive Director

AMERICAN ASSOCIATION FOR CANCER RESEARCH, INC.

Temple University School of Medicine
West Building, Room 301
Broad and Tioga Streets
Philadelphia, PA 19140

APPLICATION FOR MEMBERSHIP

CATEGORY OF MEMBERSHIP: Active Corresponding

NAME OF CANDIDATE: _____ DATE OF BIRTH: _____

PRESENT POSITION/TITLE: _____

INSTITUTIONAL AFFILIATION: _____

INSTITUTIONAL ADDRESS: _____

(City) (State/Province) (Country) (Postal Code)
TELEPHONE NUMBER: _____ SOCIAL SECURITY NUMBER: _____

PRIMARY FIELD OF RESEARCH (Please check only one):

____ Biochemistry and Biophysics ____ Biostatistics ____ Carcinogenesis
____ Cellular Biology and Genetics ____ Clinical Investigations ____ Endocrinology
____ Epidemiology ____ Immunology ____ Molecular Biology and Genetics
____ Preclinical Pharmacology and Experimental Therapeutics
____ Virology ____ Other: _____

(Please specify)

ACADEMIC DEGREES (Including where and when granted)

EXPERIENCE SINCE HIGHEST DEGREE WAS GRANTED (Please list most recent first)

PUBLICATIONS (Reprints of two articles on which the candidate appears as an author must accompany this application. For these two articles list the authors, title, journal, volume, inclusive pages, and year. Do not submit abstracts.)

CANDIDATE NOMINATED BY: _____
(Please type or print)

CANDIDATE SECONDED BY: _____
(Please type or print)

STATEMENT OF SUPPORT (in place of letters of recommendation)

Instead of submitting letters of recommendation, either the nominator or the seconder or both may complete the following section:

How long has the candidate worked in the field of cancer research? ____ years

Will the candidate make a long-term contribution to cancer research? ____ Yes ____ No

Does the candidate's research adhere to accepted ethical standards? ____ Yes ____ No

I therefore recommend this candidate for membership in the American Association for Cancer Research.

How long has the candidate worked in the field of cancer research? ____ years

Will the candidate make a long-term contribution to cancer research? ____ Yes ____ No

Does the candidate's research adhere to accepted ethical standards? ____ Yes ____ No

I therefore recommend this candidate for membership in the American Association for Cancer Research.

Signature of nominator Date

Signature of seconder Date

See Guidelines for Application on the reverse side of this form for further instructions.



AMERICAN ASSOCIATION FOR CANCER RESEARCH

SEVENTY-NINTH ANNUAL MEETING

NEW ORLEANS CONVENTION CENTER, NEW ORLEANS, LOUISIANA

MAY 25-28, 1988

SCIENTIFIC SYMPOSIA

Wednesday, May 25: "Drug Resistance from the Molecular Level to Clinical Management"

Co-Chairmen: David A. Van Echo, University of Maryland Cancer Center, Baltimore, MD

Robert C. Young, National Cancer Institute, Bethesda, MD
(sponsored jointly with the American Society of Clinical Oncology)

The widespread availability of drug-resistant human tumor cell lines and the techniques of molecular biology now allow rigorous investigation of the mechanism of multidrug resistance. The identification of genes responsible for multidrug resistance, the cytogenetic localization of growth regulatory sequences, and subcellular targets for drug injury have greatly increased our understanding of the problem and now suggest new clinical strategies to overcome drug resistance.

Michael M. Gottesman, National Cancer Institute, Bethesda, MD
Jeffrey M. Trent, University of Arizona Cancer Center, Tucson, AZ
Leroy F. Liu, Johns Hopkins University School of Medicine, Baltimore, MD
Robert F. Ozols, National Cancer Institute, Bethesda, MD
Robert L. Capizzi, Bowman Gray School of Medicine, Winston-Salem, NC

Thursday, May 26: "Approaches to the Prevention of Cancer"

Chairman: Emmanuel Farber, University of Toronto, Toronto, Canada

There are three possible approaches to the prevention of cancer development: (1) the removal or neutralization of the etiological agent(s), (2) the modulation of the metabolism so as to minimize the primary effects of carcinogens on target tissues, and (3) the interruption of the long process of tumor progression and prevention of the slow cellular evolution from an early precursor lesion to cancer. Some of these approaches are to be discussed in some detail using cancer development in different particular organs as examples.

Emmanuel Farber

Lee W. Wattenberg, University of Minnesota, Minneapolis, MN
Jose Russo, Michigan Cancer Foundation, Detroit, MI
W. Robert Bruce, Ludwig Institute for Cancer Research, Toronto, Canada
Wallace H. Clark, Jr., University of Pennsylvania, Philadelphia, PA

Friday, May 27: "New Approaches to the Discovery of Anticancer Agents"
Chairman: Frederick A. Valenote, Wayne State University, Detroit, MI

During the past few years greater use of in vitro human cell lines, more emphasis on murine solid tumors, and the use of novel targets are producing striking new leads in drug development. Examples of each aspect of these changes will be presented together with information on chemotherapeutic agents which promise to lead to the next generation of cytotoxics.

Thomas H. Corbett, Wayne State University, Detroit, MI
Warren E. Ross, University of Florida, Gainesville, FL
Nathan A. Berger, Case Western Reserve University, Cleveland, OH
Gerald B. Grindey, Lilly Research Laboratories, Indianapolis, IN
Robert C. Jackson, Warner-Lambert Company, Ann Arbor, MI
Terrence W. Doyle, Bristol-Myers Company, Wallingford, CT

Friday, May 27: "Growth Factors, Oncogenes, and the Control of Proliferation"
Chairman: W. Jackson Pledger, Vanderbilt University, Nashville, TN

Cellular and molecular biological research has provided many new insights into the control of cellular proliferation, the development of neoplastic transformation, the regulation of proliferation by growth factors, and the relationship of growth factors and growth factor modulated cellular pathways to oncogenes and cancers. New and promising advances in these areas will be addressed, with a major emphasis on basic scientific rationale and clinical application.

Charles D. Stiles, Dana-Farber Cancer Center, Boston, MA
Harold L. Moses, Vanderbilt University, Nashville, TN
Dennis J. Slamon, University of California, Los Angeles, CA

Friday, May 27: "Tumor Suppressor Genes — Mechanistic Aspects"
Chairman: Webster K. Cavenee, Ludwig Institute for Cancer Research, Montreal, Canada

Molecular biological analyses of cancer patients, their tumors, and their families have greatly increased our understanding of the chromosomal and genetic basis of human cancer. These investigations are also yielding novel conceptual and methodological approaches towards distinguishing between tumor subtypes and providing for accurate tools for prediction of tumor development. Each of these avenues of inquiry will be addressed with special emphasis on the genetic analysis of loci whose mutant forms predispose to disease.

Bernard E. Weissman, Children's Hospital of Los Angeles, Los Angeles, CA
Helmut Zarbl, Massachusetts Institute of Technology, Cambridge, MA
Walter F. Bodmer, Imperial Cancer Research Fund, London, England
John D. Minna, National Cancer Institute, Bethesda, MD

EMPLOYMENT REGISTER

Detailed listings of available positions and prospective candidates will be available for consultation during the annual meeting and will be published in the *Proceedings* and in two issues of the Association's journal *Cancer Research*. Interviews will be scheduled in New Orleans.

Fees

Member Registration:	\$65*
Nonmember Registration: (includes <i>Proceedings</i>)	\$110*
Predoctoral Student Registration: <i>Proceedings of the AACR</i>	\$35*
Employment Register: Employers:	\$20
Candidates:	\$35
	\$10

*\$10 Discount if received by April 29, 1988

SPECIAL LECTURES

Twenty-eighth G. H. A. Clowes Memorial Award Lecture

"Critical Factors in the Biology of Human Cancer Metastasis."
Isaiah J. Fidler, M. D. Anderson Hospital and Tumor Institute, Houston, TX

Twelfth Richard and Hinda Rosenthal Award Lecture

"Human Models of Susceptibility to Neoplasia."
Frederick P. Li, National Cancer Institute, Boston, MA

Seventh Rhoads Memorial Lecture

"Molecular Genetics of Human Familial Cancer."
Webster K. Cavenee, Ludwig Institute for Cancer Research, Montreal, Canada

Seventh Cain Memorial Lecture

"Oxazaphosphorine Cytostatics: Past — Present — Future."
Norbert Brock, ASTA Pharma AG, Bielefeld, Federal Republic of Germany

Presidential Address

"Immunomodulation by Anticancer Agents."
Enrico Mihich, Roswell Park Memorial Institute, Buffalo, NY

SCIENTIFIC AND PUBLIC EDUCATION SYMPOSIUM

Wednesday, May 25: "The Status of Cancer Treatment: 1988"

Chairman: Harris Busch, Baylor College of Medicine, Houston, TX

Bruce A. Chabner, National Cancer Institute, Bethesda, MD
Emil Frei III, Dana-Farber Cancer Center, Boston, MA
Donald L. Morton, University of California, Los Angeles, CA
Alan Yagoda, Memorial Sloan-Kettering Cancer Center, New York, NY

METHODS WORKSHOP

Saturday, May 28: "Cloning, Expressing, and Modifying Genes and Gene Products"

Chairman: Martin Rosenberg, Smith, Kline & French Laboratories, King of Prussia, PA

A presentation of state-of-the-art methods and techniques being used in gene cloning and expression, including new developments in protein engineering and the expression of gene products in a variety of recombinant systems. An additional registration fee of \$10 will be required to cover incidental expenses. Advance registration strongly suggested.

Martin Rosenberg
Charles Craik, University of California, San Francisco, CA
Derk Bergsma, Smith, Kline & French Laboratories, King of Prussia, PA
Mitchell Reff, Smith, Kline & French Laboratories, King of Prussia, PA

SLIDE AND POSTER SESSIONS

Two thousand abstracts were received from scientists all over the world. Slide and poster sessions will be scheduled on all four days of the meeting in the fields of Biochemistry, Biology, Carcinogenesis, Clinical Investigations, Endocrinology, Epidemiology, Experimental Therapeutics, Immunology, Molecular Biology/Virology, and Preclinical Pharmacology.

MINISYMPOSIA and POSTER DISCUSSION SESSIONS

Special slide and poster formats providing stimulating overviews of certain timely areas in cancer research will be constructed from submitted abstracts and will be scheduled throughout the meeting.

The topics of the minisymposia are immunopotentiality by chemotherapeutic agents, breast cancer, biochemical modulation, signal transduction and protein kinase, ether lipid analogs and other membrane-active chemotherapeutic agents, mechanisms of tumor promotion, DNA adducts, cytotoxic cells and cell therapy, and oncogenes and progression. The poster discussion sessions are devoted to invasion and metastasis, pediatric oncology, clinical pharmacology, carcinogen adducts with macromolecules, clinical and experimental studies of P-glycoprotein, virology, drug screening, nutrition and carcinogenesis, biochemical and molecular factors in drug resistance, and eicosanoids and other lipids.

NETWORKING FOR YOUNG INVESTIGATORS

The Program Committee has organized ten roundtable discussion groups during the lunch hour on Wednesday, May 25, for informal discussions between young investigators and prominent researchers. Participation will be on a first-come, first-served basis and will be limited to seven young investigators per roundtable. Sign-up sheets will be posted in the Registration Area as of noon on Tuesday, May 24.

PUBLICATIONS

The Proceedings of the American Association for Cancer Research contains all abstracts deemed acceptable by the Association's Program Committee and extended abstracts of special lectures. The *Proceedings* is received by all subscribers to the journal *Cancer Research*, or it may be purchased at the time of registration for \$20.

The joint Program of the Annual Meetings of the American Association for Cancer Research and the American Society of Clinical Oncology is included in the registration fee.

Deadlines


Advance Registration: (includes advance mailing of Program and <i>Proceedings</i>)	March 29, 1988
Housing Applications:	April 25, 1988
Reduced Registration Fees:	April 29, 1988
Workshop Advance Registration:	May 6, 1988
Employment Register:	May 11, 1988

Air Travel and Car Rental

McGettigan Corporate Planning Services
834 Chestnut Street
Philadelphia, PA 19107-5104
800-523-4614
215-931-1219 (in Pennsylvania)

INFORMATION AND FORMS

American Association for Cancer Research
Temple University School of Medicine
West Building, Room 301
Philadelphia, PA 19140
215-221-4565



What will you tell her about screening mammography?

Many of your patients will hear about screening mammography through a program launched by the American Cancer Society and the American College of Radiology, and they may come to you with questions. What will you tell them?

We hope you'll encourage them to have a screening mammogram, because that, along with

your regular breast examinations and their monthly self examinations, offers the best chance of early detection of breast cancer, a disease which will strike one woman in 10.

If you have questions about breast cancer detection for asymptomatic women, please contact us.



Professional Education Dept.
National Headquarters
90 Park Avenue
New York, New York 10016
or your local society



American
College of
Radiology

1891 Preston White Drive
Reston, Virginia 22091
(703) 648-8900